PSMA-targeted bispecific Fab conjugates that engage T cells.

Area of Science:

• Bioconjugation Chemistry
• Immunotherapy
• Antibody Engineering

Background:

• Bispecific antibodies offer advanced antigen targeting strategies.
• Antibody formats are being explored for enhanced therapeutic applications.

Purpose of the Study:

• To generate and evaluate PSMA-targeted Fab conjugates using novel bispecific formats.
• To assess the efficacy of these conjugates in prostate cancer models.

Main Methods:

• Generation of PSMA-targeted Fab conjugates via interchain disulfide bridging.
• Utilized two formats: SynFab (small molecule DUPA) and BisFab (αPSMA Fab).
• Optimized reducing conditions for selective disulfide reduction and yield.

Main Results:

• Both SynFab and BisFab formats demonstrated potent in vitro cytotoxicity against prostate cancer cell lines.
• Conjugates exhibited excellent antigen selectivity.
• Optimization of reducing conditions was crucial for successful bioconjugate formation.

Conclusions:

• Novel bispecific antibody formats (SynFab and BisFab) are effective for PSMA-targeted therapy.
• These bioconjugates represent promising strategies for prostate cancer treatment.
• Further development of antibody-drug conjugates is warranted.